MHSPC
Clinical trials for MHSPC explained in plain language.
Never miss a new study
Get alerted when new MHSPC trials appear
Sign up with your email to follow new studies for MHSPC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to keep prostate cancer in check with lower chemo dose
Disease control Not yet recruitingThis study tests a combination of darolutamide, hormone therapy, and a lower dose of the chemotherapy drug docetaxel in men with metastatic hormone-sensitive prostate cancer. The goal is to see if this approach can keep PSA levels very low (below 0.2 ng/mL) at 24 weeks while redu…
Matched conditions: MHSPC
Phase: PHASE2 • Sponsor: Yonghong Li • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Could a supplement boost prostate cancer treatment?
Disease control Not yet recruitingThis early-phase trial tests whether adding a dietary supplement called LC-K76 to standard hormone therapy is safe for men with metastatic hormone-sensitive prostate cancer. Forty men will receive the supplement plus hormone therapy for 24 weeks, then be followed for another 24 w…
Matched conditions: MHSPC
Phase: EARLY_PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New test may predict prostate cancer treatment success
Knowledge-focused Not yet recruitingThis study looks at whether a test called minimal residual disease (MRD) can help predict how well treatment works in men with metastatic hormone-sensitive prostate cancer. Researchers will track 50 newly diagnosed patients to see how different gene patterns affect treatment resp…
Matched conditions: MHSPC
Sponsor: Anhui Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC